[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528458":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":24,"centralContacts":44,"locations":53,"responsibleParty":72,"collaborators":74,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":24,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":24,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":56,"whyStopped":24,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A-A.therapeutic ultrasound group","ACTIVE_COMPARATOR","1. Participants: Age between 20-100 years old who diagnosed as myofascial pain syndrome patients and willing to receive treatment.\n2. Intervention: Group A (A) receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.",[13,14,15],"Device: LASER","Device: Ultrasound","Drug: Prolotherapy",{"label":17,"type":10,"description":18,"interventionNames":19},"Cohort A-B.prolotherapy group","1. Participants: Age between 20-100 years old who diagnosed as myofascial pain syndrome patients and willing to receive treatment.\n2. Intervention: Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.",[13,14,15],{"label":21,"type":22,"description":23,"interventionNames":24},"Cohort B","NO_INTERVENTION","1. Participants: Age between 13-65 years old who diagnosed as idiopathic scoliosis The diagnosis of scoliosis was confirmed by antero-posterior plain Xray with Cobbs angle larger than 10 degrees.\n2. Intervention: None",null,[26,31,37],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":24},"DEVICE","LASER","LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J\u002Fcm2 at trigger point of upper trapezius muscle.",[9,17],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Ultrasound","1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.",[9,17],[36],"Therapeutic ultrasound",{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","Prolotherapy","Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.",[9,17],[43],"Hypertonic prolotherapy",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":24,"email":49},"Der-Sheng Han, Physician","CONTACT","0972-653-916","dshan1121@yahoo.com.tw",{"name":46,"role":47,"phone":51,"phoneExt":52,"email":49},"02-23717101","215001",[54],{"facility":55,"status":56,"city":57,"state":24,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"National Taiwan University Hospital Bei-Hu Branch","RECRUITING","Taipei","802","Taiwan","TW",{"type":62,"coordinates":63},"Point",[64,65],121.52639,25.05306,{"lat":65,"lon":64},[68,71],{"name":69,"role":47,"phone":70,"phoneExt":24,"email":49},"Der-Sheng Han, physician","0972653916",{"name":69,"role":47,"phone":51,"phoneExt":52,"email":49},{"type":73,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[75,78],{"name":76,"class":77},"National Science and Technology Council","FED",{"name":79,"class":6},"National Health Research Institutes, Taiwan","100528458","precision-medicine-for-nociception-sngception-and-proprioception-100528458",false,"NCT06161038","Precision Medicine for Nociception, Sngception and Proprioception.","Inclusion Criteria:\n\n1.Cohort A:\n\n(1) Age between 20-100 years old. (2) VAS\\>=30 or VAS\\>=30 at 4 kg pressure (3) Diagnosed as myofascial pain syndrome patients and willing to receive treatment (including LLLT, therapeutic ultrasound, and local dextrose injection therapy) 2. Cohort B:\n\n1. Age between 13-65 years old.\n2. Diagnosed as idiopathic scoliosis The diagnosis of scoliosis was confirmed by antero-posterior plain Xray with Cobbs angle larger than 10 degrees.\n\nExclusion Criteria:\n\n1.Cohort A: Those having active infection, malignancy, and hematological diseases were excluded. The patients had received local injection at upper trapezius within 6 months are also excluded.\n\n2.Cohort B:\n\n1. Those having active infection, malignancy, and hematological diseases were excluded.\n2. Those having specific etiologies of scoliosis, including congenital scoliosis due to malformation or faulty segmentation of the vertebrae and neuromuscular scoliosis due to muscular imbalance, syndromic scoliosis or degenerative scoliosis.\n3. Pregnancy.","ALL","13 Years","100 Years",{"count":90,"type":91},160,"ESTIMATED","INTERVENTIONAL",[94],"NA","Precision medicine is defined as \"an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person\" by the Precision Medicine Initiative.\n\nPatients have different response to different treatment modalities, and sore\u002Fpain medicine is no exception. In our experience, low-level laser (LLL), ultrasound, and prolotherapy can reduce sore \u002Fpain through different genetic pathway. Whether the therapeutic effect is controlled by the genetic variants of those sore \u002Fpain related genes or not, is still in debate. The aims of this study are (1) To set up next generation sequencing (NGS)-based approach to find genetic variants which can determine the response of sng\u002Fpain treatment modalities and the phenotype of idiopathic scoliosis. (2) To find possible metabolomics and proteomic markers of sng\u002Fpain. (3) To determine the algorithm of precision medicine for sng\u002Fpain control via the genetic markers.\n\nInvestigators will recruit 80 myofascial pain participant and 80 idiopathic scoliosis participant from Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital Bei-Hu Branch in 2023 and 2025. The myofascial pain participant participants will receive LLL, ultrasound, and prolotherapy, and the therapeutic effect will be recorded. The clinical trial will evaluate the Sng \u002F pain (VAS) and muscle tone of the idiopathic scoliosis participant. The blood and urine samples from the first, the second, and the third visits will be analyzed by next generation sequencing, and mass spectrometry to find the possible biomarker in 2024 and 2025. Investigators expect to develop the individualized treatment plan by means of these biomarkers. Hopefully, the results will be widely applied in the field of sore \u002Fpain medicine.",[97,98,99,100],"Rehabilitation","Pain, Shoulder","Pain, Chronic","Idiopathic Scoliosis",[102,103,104,105,39],"Sng \u002F Pain","Precision medicine","Next generation sequencing","Proprioception","2024-10-17",{"date":108,"type":109},"2024-10-21","ACTUAL",{"date":111,"type":109},"2023-10-01",{"date":113,"type":91},"2025-12-31",{"name":5,"class":6},1]